Search Results - clinical+and+disease+specializations+%3e+neurology+%3e+neurodegeneration

39 Results

Sort By:

bio-IB3

Unmet NeedAccording to the CDC, approximately 5.8-million individuals aged 65+ in the United States were living with Alzheimer’s disease in 2020 (see CDC). Alzheimer’s disease leads to memory impairment that progressively affects the ability of individuals to conduct daily tasks and worsens with time. Currently, the diagnosis of Alzheimer’s disease...

Published: 3/12/2026 | Inventor(s): Esther Oh, Stina Tucker, David Borchelt, Juan Troncoso

Keywords(s): Alzheimer's Disease, Antibodies, Biologics, CNS and Neurological Disorders, Discovery/Research Tools, Disease Indication, Neurodegeneration, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Translational Research Biomarker

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Geriatrics, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Research Tools > Antibodies, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Neurology, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration

Compositions and Methods for Treatment of Eye Diseases

Unmet NeedOxidative stress contributes to the progression of multiple eye disorders, including retinitis pigmentosa, age-related macular degeneration, and diabetic retinopathy. Ocular oxidative stress is caused by an imbalance of antioxidants and pro-oxidants in the eye, leading to elevated levels of free radicals. Free radicals contribute to the damage...

Published: 3/13/2026 | Inventor(s): Peter Campochiaro, Andrea Cook

Keywords(s): Disease Indication, Eye Disorders, Non-novel, Predicted Novelty, Retinitis pigmentosa, Single, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Ophthalmology > Retinitis Pigmentosa, Clinical and Disease Specializations > Rare Diseases

SCA12 Tools – SCA12 Fibroblasts, iPSCs and Polyclonal Antibodies to Investigate SCA12

Value PropositionFirst in class patient-derived biological tools for investigation of SCA12, a rare neurodegenerative disease with no known cure. Unmet NeedSpinocerebellar ataxia type 12 (SCA12) is a rare neurodegenerative disease that affects the cerebellum, commonly resulting in upper limb tremors and muscle spasms, with some patients reporting a...

Published: 3/13/2026 | Inventor(s): Russell Margolis, Pan Li, Christopher Ross

Keywords(s): Basic Research Biomarker, Cell Lines, Discovery/Research Tools, Human Cell Lines, In Vitro Research Tool

Category(s): Technology Classifications > Research Tools > Human Cell Lines, Clinical and Disease Specializations > Neurology > Neurodegeneration

Therapeutic to Block Toxic Protein Spread in Neurodegeneration

Value Proposition· Disease-Modifying Mechanism: Elevates fibrinogen-like protein 1 (FGL1) in the brain to inhibit proteinopathies (spread of toxic proteins in the brain).· Versatile Delivery Options: Flexible treatment strategies including gene therapy, exosome delivery, and blood exchange to deliver FGL1.· Dual application: Functions...

Published: 3/13/2026 | Inventor(s): Xiaobo Mao, Ted Dawson, Valina Dawson, Wenjing Wang, Junkai Hu, Mingyao Ying, Jun Wang

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology > Parkinson’s Disease, Clinical and Disease Specializations > Neurology > Parkinson's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Alzheimer's Disease

Method to Inhibit Toxic Pathways Activated in Genetic ALS/FTD

Value PropositionTreatment readily acts via subcutaneous injection and crosses the blood-brain barrier without extra formulation or drug delivery mechanism.Treatment significantly reduces pathological and behavioral phenotypes from toxic proteins coded by genetic defects in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), which...

Published: 3/13/2026 | Inventor(s): Shuying Sun, Zhe Zhang

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Motor Neuron Diseases, Clinical and Disease Specializations > Neurology > Dementia, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics > Biomarkers

Mitigation of Nuclear Pore defect in Neurodegeneration: ESCRT Pathway Inhibition

Value PropositionNovel Target: CHMP7, a nuclear pore protein, identified as a key driver in ALS, offers a new therapeutic approach.Disease-Modifying Method: Targets the root cause of nuclear pore complex injury and neural injury, aiming to alter disease progression.Druggable Target: CHMP7 can be inhibited using small molecule, gene, and peptide therapies.Broad...

Published: 3/13/2026 | Inventor(s): Jeffrey Rothstein, Alyssa Coyne

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Clinical and Disease Specializations > Neurology > Dementia, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Huntington's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration, Technology Classifications > Therapeutic Modalities > Targets

Inhibition of rip kinases for treating neurodegenerative disorders

Unmet NeedNeurodegenerative disorders are a heterogeneous group that includes Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), dementia, and Huntington’s disease. These disorders result from progressive degeneration of the structure, function, and network of neurons in the central nervous...

Published: 3/13/2026 | Inventor(s): Seulki Lee, Han Seok Ko, Ted Dawson, Martin Pomper, Donghoon Kim, Yumin Oh, Seung-Hwan Kwon, Yong Joo Park

Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Neurodegenerative Diseases, Parkinson's Disease, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Parkinson’s Disease

Conversion of retinal glia into neurons for cell replacement therapy

Value Proposition· Identifies targets for modulation of retinal Muller glia-derived neurogenesis.· Demonstrates efficacy of adeno-associated virus induced retinal Muller glia-derived neurogenesis.· Combines viral constructs and small molecules to generate specific subtypes of retinal Muller glia-derived neurons.· Applicable...

Published: 3/13/2026 | Inventor(s): Seth Blackshaw, Thanh Hoang

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Neurodegeneration, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Cell Therapies

Novel Therapeutic Drug for Multiple Sclerosis

INVENTION NOVELTY This molecule, through its action on a unique target that is different from current therapeutic treatments for MS, has both immunosuppressive and neuromodulatory properties that will better prevent the progression of MS and repair the neuronal damage caused by the immune cells in MS. Currently, there are no MS drugs in the market...

Published: 3/13/2026 | Inventor(s): Paul Kim, Michael Kornberg, Peter Calabresi, Solomon Snyder

Keywords(s): Chronic Inflammatory Diseases, CNS and Neurological Disorders, Disease Indication, Multiple Sclerosis, Multiple Sclerosis (MS), Neurodegeneration, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

The Efficacy of Nanozyme in Neurodegenerative Diseases

Unmet NeedOxidative stress and subsequent prion-like pathology is an essential driver n the pathogenesis of neurodegenerative diseases, including Parkinson’s Disease (PD and Alzheimer’s disease (AD). Currently, only symptomatic treatments are available, and there is a great unmet need to develop a cure. Technology OverviewDisclosed herein are novel...

Published: 3/13/2026 | Inventor(s): Xiaobo Mao, Shuya Li, Weiwei He

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Parkinson's Disease, Clinical and Disease Specializations > Neurology > Parkinson’s Disease, Technology Classifications > Therapeutic Modalities > Proteins

1 2 3 4